ONCY CMO granted 260,000 stock options

ONCOLYTICS BIOTECH INC reported that Chief Medical Officer Thomas Charles Heineman received a grant of stock options as part of his compensation.

Rhea-AI Filing Summary

ONCOLYTICS BIOTECH INC reported that Chief Medical Officer Thomas Charles Heineman received a grant of stock options as part of his compensation. The award covers 260,000 stock options for common shares at an exercise price of $1.06 per share, matching the closing price on June 1, 2026. These options expire on June 1, 2036 and vest in three equal annual installments starting on June 1, 2027, conditional on his continued service or employment on each vesting date. After this grant, he holds 260,000 stock options directly.

Insider Trade Summary

Grant/Award: 260,000 shares

Grant/Award 1 txn

Insider Heineman Thomas Charles

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option	260,000	$0.00	$0.00

Holdings After Transaction: Stock Option — 260,000 contracts (Direct)

Footnotes (2)

1. F1. The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Capital Market on the date of grant, June 1, 2026.
2. F2. The stock option vests in three equal annual installments with the first tranche vesting on June 1, 2027, subject to the Reporting Person's continued service or employment, as applicable, on each such vesting date.

Key Figures

Stock options granted: 260,000 options Exercise price: $1.06 per share Expiration date: June 1, 2036 +2 more

5 metrics

Stock options granted 260,000 options Grant to Chief Medical Officer on June 1, 2026

Exercise price $1.06 per share Equal to closing price on June 1, 2026

Expiration date June 1, 2036 Option term for 260,000 granted options

Vesting schedule 3 equal annual tranches First vesting on June 1, 2027, subject to continued service

Options held after grant 260,000 options Total derivative position directly held following transaction

Key Terms

Stock Option, exercise price, vests in three equal annual installments, Common Shares

4 terms

Stock Option financial

"security_title: "Stock Option""

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

exercise price financial

"The exercise price is equal to the closing price of the Issuer's common stock"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vests in three equal annual installments financial

"The stock option vests in three equal annual installments with the first tranche vesting"

Common Shares financial

"underlying_security_title: "Common Shares""

Common shares are the basic units of ownership in a company that give holders a claim on profits and a right to vote on key matters, like electing the board. Think of them as membership cards in a club: they let you share in successes and losses, but in a bankruptcy or liquidation they are paid after creditors and preferred shareholders, so their value can swing more and matters for assessing risk and potential return.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did ONCY report for Thomas Charles Heineman?

ONCOLYTICS BIOTECH INC reported that Chief Medical Officer Thomas Charles Heineman received a grant of 260,000 stock options. These options relate to common shares and represent a compensation award rather than an open-market purchase or sale of existing stock.

What is the exercise price of the new ONCY stock options granted to the CMO?

The stock options granted to ONCY’s Chief Medical Officer have an exercise price of $1.06 per share. Footnotes state this equals the closing price of the issuer’s common stock on the Nasdaq Capital Market on the June 1, 2026 grant date.

When do Thomas Heineman’s ONCY stock options vest?

The stock options vest in three equal annual installments beginning on June 1, 2027. Each tranche requires Thomas Heineman’s continued service or employment with ONCOLYTICS BIOTECH INC on the applicable vesting date for the corresponding portion of the award to vest.

When do the ONCY stock options granted to the CMO expire?

The 260,000 stock options granted to the Chief Medical Officer expire on June 1, 2036. This expiration date gives a ten-year window from the June 1, 2026 grant date during which vested options can potentially be exercised at the stated exercise price.

How many ONCY stock options does Thomas Heineman hold after this grant?

Following this transaction, Thomas Heineman is reported to hold 260,000 stock options directly. The Form 4 shows this total in the “shares following transaction” field and does not list any additional derivative holdings in the derivative position summary.

Is the ONCY CMO’s option grant an open-market stock purchase?

No, the Form 4 describes the transaction as a grant or award acquisition of stock options. The options were awarded at an exercise price of $1.06 and reflect compensation, not an open-market purchase of ONCOLYTICS BIOTECH INC common shares on an exchange.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/03/2026 - 04:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Heineman Thomas Charles

(Last) (First) (Middle)

C/O ONCOLYTICS BIOTECH INC.

4350 EXECUTIVE DRIVE, SUITE 325

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ONCOLYTICS BIOTECH INC [ ONCY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$1.06(1)	06/01/2026		A		260,000		(2)	06/01/2036	Common Shares	260,000	$0	260,000	D

Explanation of Responses:

1. The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Capital Market on the date of grant, June 1, 2026.

2. The stock option vests in three equal annual installments with the first tranche vesting on June 1, 2027, subject to the Reporting Person's continued service or employment, as applicable, on each such vesting date.

	/s/ Kirk Look, Attorney-in-Fact	06/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)